Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

NCT03397134 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

515

Enrollment

INDUSTRY

Sponsor class

Conditions

Negative Symptoms of Schizophrenia

Interventions

DRUG: Placebo Oral Tablet
DRUG: Roluperidone 32 mg
DRUG: Roluperidone 64 mg

Sponsor

Minerva Neurosciences